EMBC
HealthcareEmbecta Corp. · Drug Manufacturers - Specialty & Generic · $200M
What is Embecta Corp.?
Embecta Corp. is a small-cap medical device company dedicated to improving life for people living with diabetes. Spun off from Becton, Dickinson and Company in April 2022, it operates as an independent, Nasdaq-listed business headquartered in Parsippany, New Jersey.
Embecta designs, manufactures, and distributes diabetes care products — primarily pen needles, syringes, and safety devices — to wholesalers and distributors across the United States and international markets. The company also offers digital applications intended to help patients manage their diabetes day to day. Revenue is driven largely by recurring demand for consumable injection devices, a category where patients require ongoing replenishment throughout their lives.
Embecta's roots trace back to 1924, though it began operating as an independent public company in 2022.
- Pen needles for insulin delivery
- Syringes and safety injection devices
- Digital diabetes management applications
- International distribution through wholesale channels
Is EMBC a Good Stock to Buy?
UQS Score rates EMBC as Good overall, reflecting a balanced but nuanced profile across its five quality pillars.
The Valuation pillar stands out as Attractive, suggesting the market may not be fully pricing in the company's fundamentals relative to peers. The Quality pillar also registers as Good, indicating the underlying business generates reasonably stable financial results for its size and sector.
Both the Moat and Growth pillars are rated Weak, pointing to limited competitive differentiation and constrained near-term expansion prospects — meaningful considerations for long-term investors.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does EMBC pay dividends?
Yes — Embecta Corp. pays a dividend.
Embecta pays a regular dividend, which is relatively uncommon among small-cap medical device spinoffs. The dividend reflects the company's ability to generate cash from its established consumable product lines. Investors seeking income alongside healthcare exposure may find this noteworthy, though the sustainability of the payout should be weighed against the Weak Growth and Moat pillar ratings.
When does EMBC report earnings?
Embecta Corp. reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
As a focused diabetes device business, Embecta's quarterly results tend to reflect the steady but slow-moving demand patterns of consumable medical products. Investors should watch commentary on pricing power and international volume trends, given the Weak Moat and Growth signals in the UQS profile.
For the most recent quarter's results and upcoming reporting dates, visit Embecta's official investor relations page.
EMBC Price History
-68.5% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Embecta Corp.?
Based on Embecta Corp.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
EMBC Long-term Outlook
Embecta's fundamental outlook is shaped by two competing forces: a stable, recurring revenue base from consumable diabetes devices on one side, and limited growth catalysts and competitive differentiation on the other. The Weak Growth pillar suggests the business is not expected to expand rapidly, while the Neutral Risk pillar indicates the company is not in acute financial distress. The Attractive Valuation pillar may offer a margin of safety for patient investors willing to accept modest near-term growth.
Growth drivers
- Recurring demand for consumable injection devices among a growing global diabetic population
- Potential expansion in international distribution markets
- Digital health applications as a supplementary revenue and retention tool
Key risks
- Weak competitive moat leaves pricing power vulnerable to lower-cost alternatives
- Limited growth pipeline following the spinoff from Becton, Dickinson
- Dividend sustainability under pressure if cash generation weakens
EMBC vs Peers
Embecta operates in a niche corner of the healthcare sector, and its listed peers span different business models within the broader health and life sciences space.
DRI Healthcare Trust focuses on royalty-based healthcare financing rather than device manufacturing, offering a fundamentally different risk and return profile.
Canopy Growth operates in cannabis-derived health products, sharing the healthcare adjacency but with an entirely different regulatory and commercial environment.
Kamada is a specialty plasma-derived protein therapeutics company, competing in a different therapeutic category but similarly serving chronic-condition patient populations.
Frequently Asked Questions
What does Embecta Corp. do?
Embecta Corp. develops and distributes medical devices for people living with diabetes, including pen needles, syringes, and safety injection devices. The company also offers digital tools to support diabetes self-management. It sells primarily through wholesalers and distributors in the US and internationally.
Does EMBC pay dividends?
Yes, Embecta pays a regular dividend. This is relatively uncommon for a small-cap spinoff in the medical device space. Investors should review the company's most recent financial disclosures to assess the dividend's ongoing sustainability in light of its growth and moat profile.
When does EMBC report earnings?
Embecta reports on a quarterly cadence, as is standard for US-listed companies. For the exact schedule and most recent results, check Embecta's investor relations page directly, as our data source does not cover specific upcoming earnings dates.
Is EMBC a good stock to buy?
UQS Score rates EMBC as Good overall. The Valuation pillar is Attractive and Quality is Good, but the Moat and Growth pillars are both Weak. Whether that profile suits your portfolio depends on your investment goals. The full pillar breakdown is available to UQS Pro members.
Is EMBC overvalued?
Based on the UQS Valuation pillar, EMBC is rated Attractive — meaning the stock does not appear overvalued relative to its fundamentals when assessed through the UQS framework. That said, valuation should always be considered alongside the company's growth and moat characteristics.
How does EMBC compare to its competitors?
Embecta's listed peers — DRI Healthcare Trust, Canopy Growth, and Kamada — operate in different corners of the healthcare sector. Embecta's focus on consumable diabetes devices gives it a recurring revenue dynamic that differs from royalty models or therapeutics businesses. See the full UQS comparison for a pillar-by-pillar view.
What is EMBC's market cap bracket?
Embecta Corp. is classified as a small-cap company. This places it in a segment of the market that can offer growth potential but also carries higher volatility and liquidity risk compared to large- or mega-cap healthcare peers.
Who founded Embecta Corp.?
Embecta's product heritage dates to 1924, when the underlying diabetes device business was part of Becton, Dickinson and Company. Embecta became an independent public company on April 1, 2022, following a spinoff. Details on the founding leadership team are available through Embecta's public filings.
Is EMBC a long-term quality investment?
As a long-term quality indicator, EMBC's UQS profile is mixed. The Good Quality pillar and Attractive Valuation suggest a degree of financial stability, but the Weak Moat and Weak Growth pillars raise questions about the company's ability to compound value over time. Long-term investors should weigh these factors carefully.
What is the main competitive advantage of Embecta Corp.?
Embecta benefits from an established distribution network and a loyal base of patients who rely on its consumable products for ongoing diabetes management. However, the UQS Moat pillar is rated Weak, suggesting these advantages may not be deeply entrenched relative to sector peers.
What sector does EMBC belong to?
Embecta Corp. operates in the Healthcare sector, specifically within the medical devices subsegment. Its focus on diabetes care consumables places it in a category driven by chronic disease prevalence and recurring patient demand rather than one-time device purchases.
Unlock Full EMBC Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access detailed financial metrics and trend data
- ✓Compare EMBC against sector peers side by side
- ✓Track valuation and quality changes over time
- ✓Get the full analyst-grade view in one dashboard
Pro Analysis
EMBC — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 57.1 | 77.4 | 32.0 | 38.6 | 46.6 | 100.0 | +0.1 |
| Apr 26, 2026 | 57.0 | 77.4 | 32.0 | 38.6 | 46.6 | 99.4 | -0.1 |
| Apr 2, 2026 | 57.1 | 77.4 | 32.0 | 38.6 | 46.6 | 100.0 | — |
EMBC — Pillar Breakdown
Quality
— 75.5/100 (25%)Embecta Corp. demonstrates outstanding capital efficiency and profitability, placing it among the highest-quality businesses in the market.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 19.1/100 (20%)Embecta Corp. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 44.6/100 (15%)Embecta Corp. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 100.0/100 (15%)Embecta Corp. appears attractively valued relative to its earnings, cash flows, and sector peers.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 32/100 (25%)Embecta Corp. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for EMBC.
Score Composition
Financial Data
More Stock Analysis
How is the EMBC UQS Score Calculated?
The UQS (Unified Quality Score) for Embecta Corp. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Embecta Corp.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Embecta Corp. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.